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Osteoarthritis (OA) is a chronic progressive disorder that 
typically requires multiple treatment modalities over the 
course of disease. Osteoarthritis occurs frequently in older 
age, and the incidence of OA is rising owing to an aging 
population and association with obesity [1]. Older patients 
often have comorbidities and are at an increased risk of car-
diovascular, gastrointestinal (GI), and renal adverse events 
(AEs), which impact on the appropriate choice of anti-OA 
medication.
The contemporary model of evidence-based medicine is 
predicated on the principle that clinical decisions and recom-
mendations are data driven. Recommendations are based on 
the balance of relative benefits and harms of the treatment 
and patients’ values and preferences. Often, the choice of 
medication is reduced to a trade-off between desirable and 
undesirable outcomes.
While multiple guidelines exist for the treatment of OA 
[2–6], they contain varying levels of detail concerning the 
safety and side effects of OA therapies. Consequently, a 
summary of the current evidence base is timely. A working 
party was convened by the the European Society for Clinical 
and Economic Aspects of Osteoporosis, Osteoarthritis and 
Musculoskeletal Diseases (1 December, 2017) to discuss 
current knowledge on the safety of anti-OA medications. 
New systematic reviews and meta-analyses were presented 
by several members of the working party, and their research 
findings are reported in this supplement.
Paracetamol has long been widely used for analgesia in 
OA; its widespread use is driven largely by an assumption 
of relative safety and despite evidence for its poor efficacy 
in OA. In recent years, evidence is mounting for cardiovas-
cular, GI, renal, and hepatic AEs occurring with long-term 
paracetamol exposure. In this issue, Conaghan et al. provide 
a critical review of the literature on paracetamol safety, rec-
ommending a cautious approach to the use of paracetamol 
for chronic pain management in OA [7].
Non-steroidal anti-inflammatory drugs (NSAIDs) play a 
central role in the management of pain in OA. While mod-
erately effective on OA pain, NSAIDs are associated with 
wide-ranging toxicities affecting the GI, cardiovascular, 
and renal systems. In a narrative literature review, Cooper 
et al. [8] provide a synopsis of safety data on non-selective 
NSAIDs published since the Cochrane review of 2011 [9]. 
Gastrointestinal toxicity is found with all NSAIDs, which 
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may be of particular concern when treating older patients 
with OA. Cardiovascular toxicity is associated with all 
NSAIDs to some extent and the degree of risk appears to 
be drug specific. All NSAIDs have the potential to induce 
acute kidney injury, and patients with OA with co-morbid 
conditions including diabetes mellitus, hypertension, and 
heart failure are at increased risk. Further details provided 
in this analysis will facilitate a better understanding of 
the risk:benefit of using NSAIDs in OA and aid treatment 
selection.
In an accompanying article, Curtis et  al. present the 
results of a systematic literature review and meta-analysis 
of the safety of cyclo-oxygenase (COX)-2 inhibitors [10]. 
Although the COX-2 inhibitors were designed to avoid the 
GI toxicity associated with COX-1 inhibition and non-selec-
tive NSAIDs, the results of this meta-analysis show that an 
increased risk of upper GI AEs, especially abdominal pain, 
remains with the COX-2 selective inhibitor class. Cyclo-oxy-
genase-2 inhibitors have a known association with increased 
risk of cardiovascular AEs; notably, even with the removal 
of rofecoxib from this meta-analysis, the risk of heart failure 
and edema remained significant. Consequently, a cautious 
approach to the use of NSAIDs and COX-2 inhibitors in 
OA is advised, with selection of treatment tailored to the 
individual patient characteristics, and limited to intermittent 
or cyclical use rather than long-term treatment to minimize 
safety concerns.
Topical NSAIDs are generally recommended ahead of 
oral NSAIDs as an early option for the symptomatic manage-
ment of OA. Topical NSAIDs have a moderate effect on pain 
with similar efficacy to oral NSAIDs, but with a better safety 
profile owing to lower systemic absorption [9]. The findings 
of a systematic literature review and meta-analysis presented 
by Honvo et al. in this issue confirm the favorable safety 
profile of the topical route of administration of NSAIDs [11]. 
A non-significant increase in skin and subcutaneous tissue 
disorders was found, largely driven by topical diclofenac, 
which may account for the higher withdrawal rate with topi-
cal NSAIDs vs. placebo. Nonetheless, topical NSAIDs may 
be considered as safe in the management of OA, especially 
with regard to low GI toxicity.
Symptomatic slow-acting drugs for OA (SYSADOAs) 
represent a class of diverse agents that offer benefit in man-
aging the symptoms of OA, with evidence for a disease-
modifying effect in the long term in some cases [12–14]. 
Symptomatic slow-acting drugs for OA include glucosamine 
sulfate, chondroitin sulfate, diacerein, and avocado soybean 
unsaponifiables, which are widely used and it is of primary 
importance to establish their safety profiles. While some 
SYSADOAs may be considered safe for use in patients with 
OA, some concerns have been raised about the safety pro-
files of other agents. Consequently, Honvo et al. have per-
formed a systematic review and meta-analysis of the safety 
of SYSADOAs vs. placebo in OA, the findings of which are 
reported in this issue [15]. The SYSADOAs glucosamine 
sulfate and chondroitin sulfate are shown to be safe treat-
ments for patients with OA. Indeed, only the pharmaceuti-
cal-grade prescription crystalline glucosamine sulfate and 
chondroitin sulfate are recommended as safe and effective 
SYSADOAs [2, 16]. Limited evidence is available for unsa-
ponifiables, which comprise multiple products containing a 
complex mixture of many natural vegetable extracts; how-
ever, the safety of one proprietary product is demonstrated 
in this new analysis. Diacerein is also available in several 
products and is associated with some safety signals [17]; 
consequently, the usefulness of diacerein in OA should be 
assessed for each patient after consideration of the nature of 
the product, appropriate dosage, and patient characteristics 
[18].
Intra-articular hyaluronic acid (IAHA) is recommended 
as a treatment option in the case of a contraindication to 
NSAIDs, e.g., in older patients with comorbidities, and 
patients who did not respond to earlier treatment [2]. Despite 
mounting evidence for the efficacy of IAHA, particularly 
for knee OA, and the widespread use of IAHA in clinical 
practice, controversy still persists regarding the risk:benefit 
of IAHA largely because of mixed reports on safety. The 
findings of a systematic review and meta-analysis presented 
in this issue by Honvo et al. did not identify any safety issue 
with IAHA [19], although the evidence was associated with 
only “low” to “moderate” certainty owing to a lack of safety 
data reporting for IAHA, which requires further studies. It 
is possible that some reports of serious AEs associated with 
IAHA are due to the concomitant use of NSAIDs, which 
should be further investigated.
The use of opioid analgesia may be considered as a last-
resort pharmacologic therapy in OA when the pain is severe, 
when patients have not responded to other therapies, and 
when surgery is not deemed appropriate [2]. The results 
of a systematic review and meta-analysis presented here 
by Fuggle et al. confirm that there are considerable safety 
and tolerability issues surrounding the use of opioids in OA 
[20]. Oral opioids are associated with an increased risk of 
GI-, dermatologic-, and central nervous system-related AEs, 
regardless of whether the immediate- or extended-release 
formulation is used. These findings support recommenda-
tions to use opioids in OA after other analgesic options and 
only for short time periods.
Last, in preparation of the meta-analyses of the safety 
of anti-OA medications, the extensive literature review 
revealed a lack of reporting of AE data and inconsisten-
cies in the data reported. This identified a need for precise 
disease-specific guidance on the reporting of AEs in clini-
cal trial manuscripts. To close this gap, a consensus state-
ment from the European Society for Clinical and Economic 
Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal 
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Diseases Working Group published in this supplement pro-
vides specific, clear, practical, and standardized guidance 
on the reporting of AE data in manuscripts reporting the 
outcomes of clinical trials assessing drugs for OA [21], 
which will complement existing recommendations [22–24]. 
Ultimately, we hope that the findings of these new safety 
analyses will add to the evidence base from which future 
guideline updates may provide further clarity on the appro-
priate selection of anti-OA medications tailored to the indi-
vidual patient.
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